About Innovate Biopharma
Innovate Biopharma is a Healthcare company based in Raleigh (United States) founded in 2012. Small molecule drugs and imaging agent for GI disorders. Innovate Biopharma has raised $48.58 million across 12 funding rounds. Innovate Biopharma has completed 1 acquisition, including RDD Pharma. Innovate Biopharma offers products and services including INN-202, INN-217, INN-289, and INN-108. Its focus areas include Life Sciences, Gastroenterology, Drugs and Diversified. Its competitors include Ironwood Pharma, ImaginAb and Alcresta; 3 of its 3 listed competitors have raised funding.
Company details
Innovate Biopharma was founded in 2012 in Raleigh, United States, as a clinical-stage biopharmaceutical company specializing in gastroenterology. The pipeline features INN-202, a tight junction regulator in phase 3 trials for celiac disease, and INN-108, a small molecule in phase 2 for inflammatory bowel disorders and mild to moderate ulcerative colitis. An imaging agent, INN-329 (secretin), is also advanced in phase 3 trials with MRCP for non-invasive pancreaticobiliary assessment.
- Headquarters Raleigh, United States
- SectorsHealthcare
- Website innovatebiopharma.com
- Social X
- Total Equity Funding$48.58M (USD)
in 12 rounds
- Latest Funding Round$2.75M (USD), Debt – Conventional
Jan 2020
- Investments & Acquisitions
Products & Services of Innovate Biopharma
Innovate Biopharma offers a comprehensive portfolio of products and services, including INN-202, INN-217, INN-289, and INN-108.
Targets celiac disease treatment in Phase 3 trials.
Addresses nonalcoholic steatohepatitis in early clinical stages.
Focuses on Crohn’s disease subset in Phase 1 trials.
Treats ulcerative colitis and other inflammatory disorders.
Funding Insights of Innovate Biopharma
Innovate Biopharma has successfully raised a total of $48.58M across 12 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $2.75 million completed in January 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $48.58M
- Total Rounds 12
- Last Round Debt – Conventional — $2.75M
- First Round $5.33M
(Jun 2013)
Latest 10 of 12 funding rounds of Innovate Biopharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2020 | $2.75M | Debt – Conventional | – | – | – |
| May 2019 | $487,126 | Post-IPO | – | – | – |
| May 2019 | $8.74M | Post-IPO | – | – | – |
| Mar 2019 | $5.5M | Post-IPO | – | – | – |
| Oct 2018 | $5.2M | Series B | – | – | – |
| Jan 2018 | $32.75M | Series B | – | – | – |
| Jan 2018 | $4.8M | Debt – Conventional | – | – | – |
| Dec 2017 | $1.45M | Series A | – | – | – |
| May 2017 | $1M | Series A | – | – | – |
| Aug 2016 | $2.65M | Series A | – | – | – |
Investments & Acquisitions by Innovate Biopharma
Innovate Biopharma has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include RDD Pharma.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Developing targeted therapeutics and delivery systems for anorectal and GI disorders | rddpharma.com | Tel Aviv, Israel | 2008 | Oct 2019 | •••• |
Complete acquisition details for Innovate Biopharma
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Innovate Biopharma
4 dated milestones of Innovate Biopharma across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Innovate Biopharma is founded.
- Funding First funding round of $5.3M.
- Acquisition Acquires RDD Pharma.
- Funding Latest funding round, Debt – Conventional, of $2.8M.
Competitors of Innovate Biopharma
Innovate Biopharma has 3 listed competitors in our database, 3 of them funded. They include Ironwood Pharma, ImaginAb and Alcresta.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| ironwoodpharma.com | 1998 | Cambridge, United States | $206.25M | 220 | Therapeutics for gastrointestinal disorders, including linaclotide, are developed. | |
| imaginab.com | 2007 | Los Angeles, United States | $59.64M | 17 | ImaginAb is focused on developing advanced immuno-oncology imaging technologies. | |
| alcresta.com | 2011 | Newton, United States | $95.89M | 52 | Enzyme-based products for gastrointestinal disorders are developed using immobilization technology. |
Detailed competitors of Innovate Biopharma
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Imaging Diagnostics
3 companies that operate in the same segment as Innovate Biopharma (Imaging Diagnostics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Handheld ultrasound devices are developed for whole-body medical imaging. | 2011 | Guilford, Connecticut, United States | USD 350 M | USD 97.61 M | 464 | |
Robotic microsurgical systems for endoscopy are developed. | 2007 | Redwood City, California, United States | USD 733.62 M | 91 | ||
Ultrasound images are analyzed via AI-based software provided by Exo. | 2015 | Redwood City, California, United States | USD 463.39 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Innovate Biopharma
Complete news archive for Innovate Biopharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Innovate Biopharma
Innovate Biopharma was founded in 2012 and raised its 1st funding round 1 year after it was founded.
Innovate Biopharma is headquartered in Raleigh, United States. It is registered at Raleigh, North Carolina, United States.
Innovate Biopharma is a funded company, having raised a total of $48.58M across 12 funding rounds to date. The company's 1st funding round was a Series A of $2.65M, raised on Jun 2013.
Innovate Biopharma was founded in 2012 in Raleigh, United States, as a clinical-stage biopharmaceutical company specializing in gastroenterology. The pipeline features INN-202, a tight junction regulator in phase 3 trials for celiac disease, and INN-108, a small molecule in phase 2 for inflammatory bowel disorders and mild to moderate ulcerative colitis. An imaging agent, INN-329 (secretin), is also advanced in phase 3 trials with MRCP for non-invasive pancreaticobiliary assessment.
Innovate Biopharma's top competitors include Ironwood Pharma, ImaginAb and Alcresta.
Innovate Biopharma offers INN-202, INN-217, INN-289, and INN-108.
Innovate Biopharma has made 1 acquisition, including RDD Pharma.